Cargando…

Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study

The non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing–remitting MS (TREAT-MS) study collects the so far largest real-life cohort regarding utilization, long-term effectiveness, and safety of alemtuzumab, a humanized monoclonal antibody directed agai...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Hoffmann, Frank, Richter, Stephan, Engelmann, Ulrich, White, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375470/
https://www.ncbi.nlm.nih.gov/pubmed/34421780
http://dx.doi.org/10.3389/fneur.2021.620758
_version_ 1783740320646692864
author Ziemssen, Tjalf
Hoffmann, Frank
Richter, Stephan
Engelmann, Ulrich
White, Robin
author_facet Ziemssen, Tjalf
Hoffmann, Frank
Richter, Stephan
Engelmann, Ulrich
White, Robin
author_sort Ziemssen, Tjalf
collection PubMed
description The non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing–remitting MS (TREAT-MS) study collects the so far largest real-life cohort regarding utilization, long-term effectiveness, and safety of alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, in adult patients with active relapsing–remitting multiple sclerosis (RRMS). An interim analysis of baseline parameters at inclusion of a non-interventional real-world study about alemtuzumab in Germany including previous multiple sclerosis (MS) medication utilization, MS activity, severity, and duration, as well as comorbidities was performed. Of the 883 patients, 71.6% were women. Mean age was 35.7 ± 9.2 years, time since first MS symptoms (=disease duration) is 8.0 ± 6.8 years, and Expanded Disability Status Scale (EDSS) is 2.7 ± 1.8 points (range, 0.0–7.5 points). The number of relapses in the 12 and 24 months prior to inclusion were 1.6 ± 1.2 and 2.2 ± 1.8, respectively. Of the patients, 14.4% were treatment naive, while for the majority, a wide spectrum of MS disease-modifying treatments (DMTs) and treatment sequences were documented. Overall, interferon beta (IFN-beta) was reported most frequently (52.4%), followed by fingolimod (35.2%), natalizumab (34.9%), and glatiramer acetate (28.9%). Patients with longer disease duration and higher EDSS had a higher number of previous DMTs. Compared to the pivotal phase 2/3 studies, RRMS patients starting alemtuzumab treatment had a longer disease duration in real-world conditions. There was variety of different treatment sequences before the final switch to alemtuzumab. In the future, linking these treatment sequences or other baseline characteristics with effectiveness and safety outcomes might be useful to support treatment decisions. Registered at Paul-Ehrlich-Institut under NIS 281.
format Online
Article
Text
id pubmed-8375470
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83754702021-08-20 Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study Ziemssen, Tjalf Hoffmann, Frank Richter, Stephan Engelmann, Ulrich White, Robin Front Neurol Neurology The non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing–remitting MS (TREAT-MS) study collects the so far largest real-life cohort regarding utilization, long-term effectiveness, and safety of alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, in adult patients with active relapsing–remitting multiple sclerosis (RRMS). An interim analysis of baseline parameters at inclusion of a non-interventional real-world study about alemtuzumab in Germany including previous multiple sclerosis (MS) medication utilization, MS activity, severity, and duration, as well as comorbidities was performed. Of the 883 patients, 71.6% were women. Mean age was 35.7 ± 9.2 years, time since first MS symptoms (=disease duration) is 8.0 ± 6.8 years, and Expanded Disability Status Scale (EDSS) is 2.7 ± 1.8 points (range, 0.0–7.5 points). The number of relapses in the 12 and 24 months prior to inclusion were 1.6 ± 1.2 and 2.2 ± 1.8, respectively. Of the patients, 14.4% were treatment naive, while for the majority, a wide spectrum of MS disease-modifying treatments (DMTs) and treatment sequences were documented. Overall, interferon beta (IFN-beta) was reported most frequently (52.4%), followed by fingolimod (35.2%), natalizumab (34.9%), and glatiramer acetate (28.9%). Patients with longer disease duration and higher EDSS had a higher number of previous DMTs. Compared to the pivotal phase 2/3 studies, RRMS patients starting alemtuzumab treatment had a longer disease duration in real-world conditions. There was variety of different treatment sequences before the final switch to alemtuzumab. In the future, linking these treatment sequences or other baseline characteristics with effectiveness and safety outcomes might be useful to support treatment decisions. Registered at Paul-Ehrlich-Institut under NIS 281. Frontiers Media S.A. 2021-08-05 /pmc/articles/PMC8375470/ /pubmed/34421780 http://dx.doi.org/10.3389/fneur.2021.620758 Text en Copyright © 2021 Ziemssen, Hoffmann, Richter, Engelmann and White. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Ziemssen, Tjalf
Hoffmann, Frank
Richter, Stephan
Engelmann, Ulrich
White, Robin
Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
title Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
title_full Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
title_fullStr Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
title_full_unstemmed Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
title_short Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
title_sort alemtuzumab in a large real-life cohort: interim baseline data of the treat-ms study
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375470/
https://www.ncbi.nlm.nih.gov/pubmed/34421780
http://dx.doi.org/10.3389/fneur.2021.620758
work_keys_str_mv AT ziemssentjalf alemtuzumabinalargereallifecohortinterimbaselinedataofthetreatmsstudy
AT hoffmannfrank alemtuzumabinalargereallifecohortinterimbaselinedataofthetreatmsstudy
AT richterstephan alemtuzumabinalargereallifecohortinterimbaselinedataofthetreatmsstudy
AT engelmannulrich alemtuzumabinalargereallifecohortinterimbaselinedataofthetreatmsstudy
AT whiterobin alemtuzumabinalargereallifecohortinterimbaselinedataofthetreatmsstudy